MPM rounds up $140M for new biotech venture fund

MPM BioVentures' new biotech venture capital fund has been swelling quickly. Mass High Tech reports that just hours after MPM reported a first close of $69 million for its MPM BioVentures V, an amended form pushed the total to $140 million.

And it may still have some ways to go.

MPM BioVentures IV closed in the spring of 2007 with $550 million. MPM Capital manages $2.5 billion in funds. The investor has backed Waltham-based Proteon Therapeutics, TaiGen Biotechnology and Fremont, CA-based ARYx Therapeutics. It has no specific geographic focus.

- here's the story from Mass High Tech

Suggested Articles

Insitro picked up $143 million to build out its technology, pursue new targets and advance treatments for genetically defined patient groups.

Generation Bio filed for a $215 million IPO to advance a pair of gene therapies for liver disease and push one of them into the clinic.

The IPO will push Avidity's lead muscle disorder program through IND-enabling studies and into the clinic in 2021.